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CHARACTERIZATION OF THE TET2 DEMETHYLATION COMPLEX  
CLARK YIN 
ABSTRACT 
 Epigenetics encompasses the cellular mechanisms that affect gene expression 
without changing an organism’s actual DNA sequence. Currently, there are three main 
methods of cellular epigenetic gene regulation: histone modifications, DNA 
modifications, and non-coding RNAs. Histone and DNA modifications are commonly 
referred to as ‘tags’ and alter the physical and biochemical environment around the 
residue or base. Tags are recognized or removed by various protein/enzyme ‘readers’ or 
‘erasers’ that result in various changes in DNA transcription. One of the most studied 
epigenetic modifications, methylation at the 5’-position of cytosine, is successively 
oxidized by the Ten-eleven translocase (TET1, TET2, and TET3) family of enzymes and 
results in demethylation. TET2 is found in a complex with histone modifying proteins 
that link demethylation with histone modifications and eventually changes in gene 
expression. One such protein, O-linked N-acetylglucosamine transferase (OGT), is an 
enzyme that transfers N-acetylglucosamine (GlcNAc) moieties onto –OH groups of 
serine and threonine residues. Due to the co-localization of TET2 and OGT on chromatin, 
we sought to investigate the possibility of GlcNAcylated 5-hydroxymethylcytosine (5-
GlcNAc-hmC).   
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INTRODUCTION 
 
 An often referenced example of epigenetics at play is the differences that arise in 
monozygotic twins. While each twin shares identical genes, they nonetheless develop 
unique traits due to variations in gene expression. Certain genes are turned on or off due 
to epigenetic tags placed on-top of DNA; this extra level of gene expression regulation is 
the essence of epigenetics. The term “epigenetics” was first coined by Conrad 
Waddington to describe “the branch of biology which studies the causal interactions 
between genes and their products, which bring the phenotype into being” (Waddington 
2012). In his 1942 article, observations of the development of Drosophila melanogaster 
were used to describe an ‘epigenome’ that provides complex instructions to link an 
organism’s genotype to its phenotype. If an organism’s DNA and genome were to 
represent a “blueprint” of a bridge, the epigenome would be the engineers that interpret 
and modify the blueprint in order to construct the bridge (Waddington 2012; Goldberg, 
Allis, and Bernstein 2007).  
 On the molecular level, your DNA holds genetic information that was passed 
down from your parents. This long strand, which would stretch to about two meters if 
unraveled, must be packed inside of a tiny nucleus within a cell that is 5-10 µm in 
diameter. To solve this problem, the genomic DNA is wrapped around histones to form 
nucleosomes, which are then further organized into higher-order chromatin structures. 
During metaphase of mitosis, chromatin forms its most condensed organization and is 
referred to as heterochromatin. During interphase, some of the cell’s DNA is more 
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loosely packed and is referred to as euchromatin. However, this packaging leads to a 
significant problem: how are the chromatin structures dynamically regulated to allow 
cellular machinery access to the genes on your DNA for transcription into mRNA and 
later translation into proteins? Since Dr. Waddington’s time, numerous technological 
improvements have allowed for the discovery of various epigenetic mechanisms that help 
elucidate how cellular machinery unravels packed DNA via biochemical modifications 
on histone proteins as well as DNA itself. These modifications change gene expression 
by physically altering the chromatin structure or by recruiting other histone and DNA 
modifiers. These post-translational modifications can also be removed, which lends to the 
reversibility of epigenetics. The following paragraphs will explore the various epigenetic 
mechanisms starting with histone modifications, which come in varying flavors as shown 
in Figure 1.  
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Figure 1: Histone modifications. DNA is wrapped around a core of histone (histone 2A, 
histone 2B, histone 3, and histone 4) that create a globular structure with protruding tails. 
The tails are the main site of post-translational modifications such as methylation (M), 
phosphorylation (P), biotinylation, sumoylation (SUMO), ubiquitylation, and acetylation. 
Figure taken from (Goldberg, Allis, and Bernstein 2007). 
Histone Modifications – Acetylation and Deacetylation 
 Histone acetylation is the addition of an acetyl group onto a histone tail. These 
reactions are catalyzed by histone acetyltransferases (HATs), which use acetyl-CoA as 
the source of the acetyl group that is transferred to lysine residues. The modification 
commonly occurs on histones 3 (H3) and 4 (H4). This reduces the positive charge of the 
histone protein and the bound negatively charged DNA is left in a more relaxed state, 
thus allowing for transcription factors and other related proteins to bind. There are 
numerous HATs, some of which are detailed in Table 1. The opposite effect results from 
histone deacetylases (HDACs) that remove the acetyl groups and return the chromatin to 
its more tightly bound state and leads to gene repression. A recent example of the 
physiological effects of histone acetylation was demonstrated by a team of researchers at 
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the University of Pennsylvania. Simola et al. utilized carpenter ants because each colony 
is made up of nearly genetically identical sister ants with a caste system of “majors” and 
“minors”, with minors being the foragers of the colony. Intriguingly, treating developing 
majors with histone deacetylase inhibitors produced majors that exhibited minor-like 
foraging behavior (Simola et al. 2016). The implications of this study show that changes 
in gene expression via epigenetics plays a role in social behavior.  
Table 1. Selected histone acetyltransferases, sites of modification, and proposed 
functions. Histone acetyltransferases typically function as transcription activators, but 
are also involved in other important functions such as histone deposition and DNA repair. 
Multiple sites can be acetylated by the same enzyme while some sites are affected by 
different enzymes.  
Enzyme Site Proposed Function 
Tip60 (Kimura and Horikoshi 
1998) 
Histone 2A on lysine 5 Transcriptional activation 
p300/CBP (Schiltz et al. 1999) Histone 2A on lysine 5; Histone 
2B on lysine 12 
Transcriptional activation 
ATF2 (Kawasaki et al. 2000) Histone 2B on lysine 5; 
Histone 2B on lysine 12; 
Histone 2B on lysine 15 
Transcriptional activation 
Elp3 (Winkler et al. 2002) Histone 3 on lysine 14 Transcriptional activation 
TFIIIC90 (Hsieh et al. 1999) Histone 3 on lysine 14 RNA polymerase III 
transcription 
TAF1 (Mizzen et al. 1996) Histone 3 on lysine 14 RNA polymerase II 
transcription 
GCN5 (Grant et al. 1999) Histone 3 on lysine 18 Transcriptional activation and 
DNA repair 
Hat1 (Parthun, Widom, and 
Gottschling 1996) 
Histone 4 on lysine 5 Histone deposition 
  
Histone Modifications – Phosphorylation and Dephosphorylation 
 Histone phosphorylation, much like cytoplasmic protein phosphorylation, occurs 
on hydroxyl groups. Thus, the serine, threonine, and tyrosine residues on the N-terminal 
tails are frequently phosphorylated. Phosphorylation and dephosphorylation are the action 
of kinases and phosphatases, respectively. This modification is similar to histone 
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acetylation in that the charge of the histone is ultimately made more negative when added 
and leads to a more relaxed chromatin state. However, the resulting gene regulation 
varies between gene repression and activation depending on the site. Selected histone 
kinases are described in Table 2. Research on histone phosphorylation has provided 
insight on epigenetic changes and alcohol addiction and other drug-induced changes in 
gene expression. McClain and Nixon demonstrated in a mouse model that ethanol 
intoxication lead to a decrease in histone 3 serine 10 phosphorylation (H3S10ph) and that 
withdrawal led to a significant increase (McClain and Nixon 2016). 
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Table 2. Selected histone kinases (phosphorylases), sites of modification, and 
proposed functions. Histone phosphorylation is a similar modification to histone 
acetylation in that it is reversible, is carried out on specific residues, and is reversible. 
However, the downstream effects are more varied than histone acetylation.  
Enzyme Site Proposed Function 
MSK1 (Y. Zhang et al. 2004) Histone 2A on serine 1 Transcriptional repression 
NHK1 (Aihara et al. 2004)(Ahn 
et al. 2005)(Ahn et al. 2005) 
Histone 2A on threonine 119 Mitosis 
Ste20 (Ahn et al. 2005) Histone 2B on serine 10 Apoptosis 
AMPK (Bungard et al. 2010) Histone 2B on serine 36 Transcriptional activation 
 
Histone Modifications – Methylation and Demethylation 
Histone methylation is catalyzed by lysine and arginine methyltransferases. 
Methylation of lysines can come in mono-, di-, or tri-methylated forms while arginine 
methylation can result in mono-, symmetrical or asymmetrical di-methylation; in contrast 
to phosphorylation and acetylation, this modification does not affect the overall charge. 
The varying states of methylation on arginine or lysine is depicted in Figure 2. Both 
lysine and arginine methyltransferases utilize S-adenosylmethionine (SAM) as the source 
of methyl groups. Table 3 describes selected histone methyltransferases. 
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Figure 2: Histone methylation of lysine and arginine residues. Unlike acetylation and 
phosphorylation, methylation of histone tails is further complicated by the fact that the 
residues have varying states of methylation. Methylation is catalyzed by histone 
methyltransferases. Figure taken from (Klose and Zhang 2007). 
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Table 3. Selected histone methyltransferases, sites of modification, and proposed 
functions. Histone methylation results in different downstream effects based on the site 
of methylation. As methylation removes the positive charge from the substrate lysine or 
arginine residue, it is expected that this modification would lead to gene repression. 
However, as demonstrated by PRMT1/6, methylation on certain locations can even lead 
to transcriptional activation.  
Enzyme Site Proposed Function 
EZH2 (Daujat et al. 2005; 
Kuzmichev et al. 2004) 
Histone 1 on lysine 26 Transcriptional silencing 
PRMT5 (Di Lorenzo and 
Bedford 2011) 
Histone 3 on arginine 2 Transcriptional repression 
PRMT1/6 (Di Lorenzo and 
Bedford 2011) 
Histone 2A on arginine 3 Transcriptional activation 
SET9 (Sanders et al. 2004) Histone 4 on lysine 20 Checkpoint response 
 
Historically similar to DNA methylation, histone methylation was also thought to 
be an unchanging epigenetic mark, i.e. permanently established on histones. It was not 
until Y.G. Shi and colleagues characterized the first histone lysine demethylase in 2004 
that this mindset was changed (Y. Shi et al. 2004). Interestingly, lysine-specific histone 
demethylase 1 (LSD1) function is regulated by its interacting partners. LSD1 exhibits a 
gene repressor function when complexed with Co-REST (corepressor of RE1 silencing 
transcription factor), but exhibits coactivator function when complex with androgen 
receptor (M. G. Lee et al. 2005; Y. Shi et al. 2004; Klose and Zhang 2007). LSD1 and its 
homologs belong to the family of FAD-dependent amino oxidases. This family 
oxidatively cleaves the carbon-carbon bond of mono-methylated lysines and 
subsequently releases formaldehyde and hydrogen peroxide as depicted in Figure 3.  
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Figure 3: Lysine demethylation via lysine-specific demethylase family enzymes. A 
mono-methylated lysine residue (Kme1) is subject to LSD demethylation using FAD and 
molecular oxygen. Hydrogen peroxide and formaldehyde are released. FAD – flavin 
adenine dinucleotide; FADH2 – reduced flavin adenine dinucleotide; H2O2 – hydrogen 
peroxide. Figure taken from Shi et al. 2004. 
 A second family of lysine demethylases was identified in 2005. Yi Zhang’s 
laboratory recognized the similarity in chemistry of the AlkB family of repair 
demethylases that removed methyl groups from methylated adenines in bacteria (Falnes, 
Johansen, and Seeberg 2002; Y. G. Shi and Tsukada 2013; Yang et al. 2008). The JmjC 
domain-containing histone demethylase 1 (JHDM1/KDM2) demethylates histone 3 at 
lysine 36 (Tsukada et al. 2006; Y. G. Shi and Tsukada 2013). As members of the Fe(II)- 
and α-ketoglutarate dependent family of enzymes, JHDM1 catalyzes an oxidation 
reaction and produces succinate and CO2 as shown in Figure XX (Tsukada et al. 2006).  
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Figure 4: Histone demethylation via JmjC-domain containing histone demethylases. 
This demethylation reaction requires α-ketoglutarate, molecular oxygen, and Fe(II) as 
cofactors. Histone demethylation by these enzymes also release formaldehyde. Figure 
taken from (Tsukada et al. 2006). 
 
With the realization that epigenetic processes are often disrupted in pathologies, 
histone demethylases have become potential therapeutic targets in the fight against cancer 
(Rotili and Mai 2011; Byler and Sarkar 2014; Heerboth et al. 2014). Overexpression as 
well as mutation of the lysine demethylases has been linked to a number of cancers 
(Højfeldt, Agger, and Helin 2013; Rotili and Mai 2011). Examples are as follows:  
overexpression of LSD1-linked cancers include breast, small cell lung, colorectal, 
prostate, and bladder cancers; reduced expression of LSD2-linked cancers include 
prostate cancer; and overexpression of JmjD2 is linked to prostate cancer (Rotili and Mai 
2011).  
Other Histone Modifications 
The list of histone modifications goes on with deimination, glycosylation, 
ribosylation, ubiquitylation, sumoylation, and proline isomerization. Poly-(ADP-
ribosylation) (PARylation) loosens chromatin structure which allows transcriptional 
factors to easily access DNA wrapped around histones (Osada, Rydén, and Masutani 
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2013). While not as extensively studied as the above mentioned modifications, these 
other histone modifications nonetheless have important physiological roles as detailed in 
Table 4. 
Table 4. Other histone modifications, sites of modification, and proposed functions. 
The other histone modifications are involved in numerous functions such as 
spermatogenesis, meiosis, and of course gene regulation.  
Modification Enzyme Site Proposed Function 
Ubiquitylation 
RNF2 (Wang et al. 
2004; Lin et al. 2015) 
Histone 2A on lysine 
119 
Spermatogenesis 
Gene repression 
UBE2E1 (B. Zhu et al. 
2005; S. Lee, Hong, and 
Kang 2008) 
Histone 2B on lysine 
120 
Meiosis 
Transcriptional repression 
Sumoylation SUMO (Nathan et al. 
2006) 
Histone 2A on lysine 
126  
Transcriptional repression 
Biotinylation Biotinidase (Kobza et al. 
2005) 
Histone 3 on lysine 4 Gene expression 
ADP Ribosylation PARP1 (Hassa et al. 
2006) 
Histone 3 Gene activation 
Proline 
Isomerization 
FPR4 (Nelson, Santos-
Rosa, and Kouzarides 
2006) 
Histone 3 Inhibition of 
methylation/transcriptional 
repression 
 
The Histone Code 
While all of the mentioned chromatin modifications affect transcription, a few of 
them also function in repair, replication, and condensation of chromatin. Most histone 
modifications will change gene expression by one of the following methods: the first is 
by altering the actual structure of the bound chromatin. The second method is when the 
histone modification affects the binding of histone modification “readers”. Histone 
acetylation and phosphorylation are linked to the first method in that they lower the 
normally positive charge of histones, thus allowing the negatively charged DNA to be 
less tightly bound to the histone. This relaxed structure allows DNA to be accessed by 
transcription enzymes (Kouzarides 2007). The cellular mechanics of histone 
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modifications have led to the proposal of the “histone code” hypothesis (Højfeldt, Agger, 
and Helin 2013; Strahl and Allis 2000; Jenuwein and Allis 2001). Strahl and Allis lay the 
foundation of this hypothesis with observations that histone acetylation and 
phosphorylation occur in recognizable patterns that result in different cellular processes. 
For example, acetylation of lysine 14 on histone 3 is specifically linked to transcription 
activation while methylation of lysine on 9 on histone 3 is linked to gene silencing (Kuo 
et al. 1996; Jenuwein and Allis 2001; X. Zhang, Wen, and Shi 2012). To further support 
this hypothesis, Pesavento et al. used top-down mass spectrometry to examine the 
modification patterns of histone 4 of HeLa cells. They found and characterized 42 unique 
combinations of methylation and acetylation, demonstrating the co-existence of different 
modifications on single nucleosomes (Sneppen and Dodd 2012; Pesavento et al. 2008). 
The various modifications on histone tails are then recognized by ‘reader’ proteins. 
Binding of the reader proteins leads to various downstream events such as gene 
transcription or gene silencing (Beaver and Waters 2015; Rothbart et al. 2012; Taverna et 
al. 2007).  The next level of epigenetic gene regulation involves modifications to the 
DNA strand itself.  
DNA Cytosine Methylation 
Arguably the most studied and best characterized modification of DNA is 
methylation of the 5’ carbon of cytosine (5mC) residues. This modification is placed by 
DNA methyltransferases (DNMTs) as demonstrated in Figure 5.  
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Figure 5. Methylation of the 5’ position of cytosine via the DNMT family enzymes. 
Depending on the context, DNMTs either methylate cytosine residues de novo, DNMT2 
and DNMT3a/b, or they methylate cytosine residues on newly replicated strands, 
DNMT1. This reaction requires S-adenosyl methionine (SAM). Figure taken from 
(Liyanage et al. 2014). 
 
This modification is typically found on cytosine residues adjacent to guanine 
(CpG) residues but can be found in a non-CpG context as well. When CpGs are found in 
dense clusters, they are termed CpG islands (CGIs). CGIs are found at promoters of many 
housekeeping genes as well as developmentally associated genes where their 
hypomethylated state allows for constitutive expression of these genes (Deaton and Bird 
2011; Larsen et al. 1992; J. Zhu et al. 2008). However, when CGIs are heavily 
methylated, 5mC can recruit methyl-CpG binding proteins (MBPs) and histone 
modifying proteins. Together, they block transcription factors from binding to DNA and 
repress gene expression as shown in Figure 6.  
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Figure 6. Examples of gene regulation via DNA cytosine methylation. Methylated 
promoters of genes are not transcribed effectively “turning off” the gene. DNA 
methylation blocks transcription factors (TFs) from binding and the downstream gene is 
repressed. Methylation can also recruit methyl-CpG binding proteins (MBPs) which 
subsequently inhibit and block gene transcription. DNA methylation is also a recruiter of 
histone modifying proteins that also cause transcriptional repression. When DNA 
methylation is found in the gene body, methylation as well as methylation-recruited 
MBPs inhibit elongation. Figure taken from (Klose and Bird 2006). 
 
Methylation is inherited during mitosis by DNA methyltransferase 1 (DNMT1) 
which recognizes a methylated parent strand and adds a methyl group to the daughter 
strand. De novo methylation is a function of DNMT3a and DNMT3b. They are able to 
methylate hemi-methylated and unmethylated CpGs at the same rate. DNMT3a and 
DNMT3b establish a strand’s methylation status which is then maintained by DNMT1.  
Functions of DNA Cytosine Methylation 
A highly conserved function of DNA methylation is the protection and 
maintenance of parasitic repeats. There are numerous tandem repeats of DNA that have 
the potential to be transcribed. Methylation of these disruptive sequences prevents their 
transcription. Methylation has also been shown to play a role in embryonic stem cell 
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commitment. Experiments have shown that methylation of DNA is not necessary for 
establishment or maintenance of pluripotency, but without DNMTs, differentiation of 
stem cells is disrupted. Aberrant methylation levels can result in immune cells becoming 
autoreactive in vitro and have also been shown to be related to autoimmunity in vivo. As 
DNA methylation typically results in gene repression, CGIs are normally 
hypomethylated, thus allowing for gene transcription. When there is methylation of CpG 
sites in gene bodies, the resulting transcription is much more complex and less clear. 
Novel functions of DNA methylation are continually discovered and has become 
recognized as an important player in maintaining the function of immune cells. Recent 
studies suggest that aberrant regulation of DNA methylation levels can result in 
autoreactivity in vitro, but also autoimmunity in vivo for example, Richardson et al.’s 
study on hypomethylation of CD4+ T cell DNA resulting in autoreactivity (Richardson, 
Ray, and Yung 2004). It is now implicated that mutations as well as environmental 
factors leading to abnormal methylation and thus affecting the expression of immune-
related genes is associated with the development of systemic lupus erythematosus, 
rheumatoid arthritis, multiple sclerosis, and even type 1 diabetes (Sun et al. 2016). As 
proper DNA methylation is critical for development, it is no surprise that aberrant 
methylation is also tightly linked to cancer and tumor progression. Numerous studies 
have demonstrate that disruption of any of the DNA methyltransferases results in lethality 
during embryonic development (Lei et al. 1996). In relation to cancer, abnormal gene 
silencing as a result of methylation is found in the normally CG-dense islands, which are 
normally hypomethylated. Epigenetic dysregulation due to viral and microbial infections 
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also demonstrate the importance of proper DNA methylation and gene transcription 
(Paschos and Allday 2010). Epigenetic modifications to a host’s genome as well as to the 
viral genome influence gene expression and intensity of infection (Wille et al. 2015; 
Galvan et al. 2015). 
DNA Cytosine Demethylation 
Historically, 5mC was viewed as a permanent epigenetic mark as well as the only 
modified base naturally present in mammalian DNA. However, in late 2009/2010, 
researchers in multiple labs had concurrently elucidated the demethylase function of the 
Ten-eleven translocase (TET) family of proteins named after the ten-eleven translocation 
(t(10;11)(q22;q23)) that is mutated in rare forms of acute myeloid lymphocytic leukemias 
(H. Zhang et al. 2010; Tahiliani et al. 2009; Ito et al. 2010). The TET family proteins are 
dioxygenases that require alpha-ketoglutarate and iron to catalyze successive oxidations 
of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-
carboxycytosine (5caC) as shown in Figure 7. 
 
Figure 7: TET family proteins mediate oxidation of 5mC. These proteins utilize α-
ketoglutarate (2-OG) and molecular oxygen while releasing succinate and CO2, much like 
the JmjC-domain containing family of histone demethylases. Figure taken from (Tan and 
Shi 2012). 
 
The latter two intermediates are then removed via thymine DNA glycosylase and 
an unmodified cytosine replaces the abasic site via the base excision repair (BER) 
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pathway. Other studies indicate that TET proteins initiate demethylation by the 
activation-induced deaminase (AID)/apolipoprotein B mRNA-editing enzyme complex 
(APOBECs) family of cytidine deaminases, which is also subsequently repaired by the 
BER pathway (Long, Blackledge, and Klose 2013). The other possibility of 
demethylation is direct removal of the carboxyl group from 5caC to produce unmodified 
cytosine by a putative decarboxylase yet to be identified. These demethylation pathways 
are summarized in Figure 8.  
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Figure 8: Summary of cytosine demethylation pathways. Starting with cytosine, 5-
methylcytosine (5mC) is produced via the DNMT family enzymes. One proposed 
mechanism involves the deamination of 5mC to produce thymine, which is recognized 
and repaired by the base excision repair pathway (BER). The first oxidation of 5mC by 
TET proteins produces 5-hydroxymethylcytosine (5hmC) which can also be deaminated 
to produce 5-hydroxymethyluracil (5hmU). 5hmU is then returned to an unmodified 
cytosine via BER. The successive oxidation products of 5hmC, 5-formylcytosine (5fC) 
and 5-carboxycytosine (5caC) have been shown to be removed by thymine DNA 
glycosylase (TDG) with the abasic site repaired by BER. Figure modified from (Tan and 
Shi 2012). 
TET Proteins 
 The discovery of TET proteins added an important aspect to the methylation 
status of an organism by proving that this modification is reversible even in adult life. In 
the years to follow, numerous examples of TET protein function were characterized. The 
TET family (TET1, TET2, and TET3) proteins are expressed in varying levels depending 
on tissue as well as stage of development. They differ in their structure, with TET1 and 
TET3 containing an N-terminal CXXC zinc finger domain that is used for DNA binding. 
The CXXC domain is highly conserved and consist of two cysteine-rich clusters that help 
coordinate two zinc ions; it is also found in DNMT1 (Long, Blackledge, and Klose 
 19 
2013). The catalytic domain of the TET proteins is cystine-rich and is located at the C-
terminal.  
TET Protein Functions 
 TET1 is highly expressed in embryonic stem cells, and has been found to repress 
developmental genes that are required to maintain pluripotency (F.-T. Shi et al. 2013). 
TET1 and TET2 are both required for proper differentiation; Dawlaty et al. found that 
knockdown of Tet1 and Tet2 in mouse embryonic stem cells led to defects in 
differentiation (Dawlaty et al. 2011). TET1 and TET2 are also important for the active 
demethylation event that occurs while primordial germ cells migrate to the gonadal ridge 
(Surani and Hajkova 2010). TET3 is highly expressed in oocytes, and is specifically 
enriched in the male pronucleus (Gu et al. 2011). Malfunctions in TET proteins from loss 
of function mutations are implicated in hematopoietic cancers, diabetes, Alzheimer’s 
disease, melanoma, and various other solid tumors (Huang et al. 2016). Huang et al. 
analyzed the mRNA levels of the TET family members in colorectal cancer cells (CRC) 
and found that TET1 protein and mRNA levels were negligible. While there was no 
difference between normal cells and CRC cells in levels of TET3, the presence of TET2 
in the nucleus was drastically reduced (Huang et al. 2016). TET1 as well as TET2 have 
been suggested as tumor suppressors. Cimmino et al. raised cohorts of TET1-deficient 
mice and monitored their health over two years. Noticeably, TET1-deficient mice began 
to show decreased survival compared to wild-type animals, and later analysis of lymph 
node, liver, and spleen tissue showed that deletion of TET1 promoted the development of 
B cell lymphoma (Cimmino et al. 2015). Another interesting process in which TET 
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proteins are implicated in is memory. Active removal of methylation which would in turn 
regulate neuronal gene expression has been shown to affect neuronal plasticity, learning, 
and memory processes. Post-mitotic neurons are frequently used to study TET proteins 
because any detectable demethylation can usually be attributed to an active 
demethylation process (Meng et al. 2014).  
5-hydroxymethylcytosine 
Interestingly, emerging evidence increasingly shows that the oxidative products of 
TET mediated 5mC demethylation are not just intermediates, they are also stable 
epigenetic marks. Most notably, the scientific community continues to discover new 
processes in which 5hmC is integral for proper cellular functioning (Vasanthakumar and 
Godley 2015). While first identified in T-even bacteriophages in the 50s, it was given 
little attention until recently, and is thought to also regulate gene expression, much like 
5mC (Wyatt and Cohen 1953). This modification is also clearly conserved across 
organisms as it was recently found to be important for Epstein-Barr virus (EBV) gene 
regulation. EBV exists in a latent or lytic phase of infection; a lytic infection is 
established in differentiated epithelial cells, but in abnormal cancer cells, EBV undergoes 
latent infection of undifferentiated epithelial cells. This astute observation was used by 
Wille et al. to demonstrate that the EBV genome can undergo hydroxymethylation of 
5mC by TET proteins, and that this modification affects whether the virus persists in a 
lytic or latent phase (Wille et al. 2015). 5hmC influences regulation of gene expression 
either by facilitating demethylation, or by disruption of recruitment of methyl-CpG 
binding proteins. 5hmC is found in increasing amounts in gene bodies, in particular, 
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intragenic portions of genes that are highly expressed. 5hmC is also found in gene 
promoters as well as transcription start sites of genes whose promoters contain two well-
known epigenetic histone modifications: H3K27me3 and H3K4me3. Levels of 5hmC 
also vary depending on tissue, with brain tissue containing the highest amounts of 5hmC 
(Kriaucionis and Heintz 2009; Münzel et al. 2010; Globisch et al. 2010). As such, this 
epigenetic mark is becoming increasingly recognized as an important modification in 
neuronal development, migration, differentiation, and pathogenesis of age-related 
neurodegeneration. Decreased levels of 5hmC were found in numerous regions of the 
brain in Alzheimer’s disease patients (Sherwani and Khan 2015; Chouliaras et al. 2013; 
Mastroeni et al. 2009; Cadena-del-Castillo et al. 2014). Loss of this TET-induced 
hallmark is characteristic of melanoma as demonstrated by Lian et al. in 2012 (Lian et al. 
2012). Melanoma is one of the deadliest skin cancers and is epigenetically characterized 
with global hypomethylation as well as hypermethylation at specific tumor suppressor 
genes. Lian et al. used these observations to explore 5hmC levels. They first determined 
that mature melanocytes and benign nevi contain significantly higher 5hmC levels vs. 
melanomas by immunohistochemical (IHC) and immunofluorescent (IF) staining. They 
then used a melanoma progression tissue microarray (TMA) to show that as melanomas 
progressed from primary to metastatic tumors, a significant decrease in 5hmC occurred. 
Because 5hmC is produced by the TET family enzymes, they looked at the expression 
levels of TET as well as IDH (isocitrate dehydrogenase) family genes of benign nevi and 
melanomas, with the hypothesis that disruption of IDH, which produces the required co-
factor α-ketoglutarate, would decrease TET function. Unsurprisingly, they found 
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significant down-regulation of IDH as well as TET in melanomas. Finally, the team 
reintroduced active TET2 in melanoma cells and found that reestablishing the 5hmC 
landscape not only inhibited tumor progression, but also inhibited tumor growth (Lian et 
al. 2012). 
The Link between TET Regulation, Gene Transcription, and 5hmC 
The production of 5hmC is but one aspect of TET family proteins. TET proteins 
commonly interact with various chromatin regulators like Sin3a, NuRD, and Mbd3. 
Using genome-wide analyses of mouse embryonic stem cells expressing either TET1 
shRNA or a scrambled shRNA, Williams et al. found that TET1 results in transcriptional 
repression. They then used protein purification and ChIP-seq analysis to find that TET1 
co-localizes with the Sin3a co-repressor. This complex is proposed to repress 
transcription via histone deacetylation (Williams et al. 2011). The NuRD/Mbd3 complex 
is yet another chromatin repressor complex that is involved in maintaining stem cell 
pluripotency and self-renewal (Yildirim et al. 2011).  
5-Formylcytosine and 5-Carboxycytosine 
Oxidation of 5mC by TET family proteins does not stop at 5hmC, and it was only 
until fairly recently that nucleotide variants such as 5-formylcytosine (5fC) and 5-
carboxycytosine (5caC) have come under increased investigation as epigenetic marks 
(Song, Yi, and He 2012). 5fC and 5caC, the products of successive oxidation of TET 
proteins on 5mC are found in much lower levels than 5mC or 5hmC as shown in Table 5. 
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Table 5. Abundance of 5hmC, 5fC, and 5caC in mouse embryonic stem cells. The 
relative abundance of the novel nucleotide bases are found in differing amounts in 
various tissues. Levels of 5hmC, 5fC, and 5caC in mouse embryonic stem cells is shown 
below. Table adapted from (Ito et al. 2011).  
Modification Relative Abundance 
5hmC 
0.1% of cytosine 
residues 
5fC  
20 p.p.m. of cytosine 
residues 
5caC 
3 p.p.m. of cytosine 
residues 
 
Pfaffeneder et al. utilized an HPLC-MS on mouse ES cells and nerve cell tissue to 
unequivocally show the existence of 5fC and 5caC in genomic DNA (Pfaffeneder et al. 
2011). Currently, further investigation is required to understand the function of these two 
nucleotide variants. However, they are recognized and removed by thymine DNA 
glycosylase (TDG) which leads to base excision repair (BER) and this suggests the 
possibility of fine-tuning gene expression (Maiti and Drohat 2011; L. Zhang et al. 2012). 
OGT, a TET Partner 
While TET’s association with chromatin-modifying complexes carry out their 
functions by affecting histones, TET’s association with O-linked N-acetylglucosamine 
transferase (OGT) introduces an interesting aspect to the demethylation pathway. OGT 
catalyzes the transfer of an O-linked N-acetylglucosamine (O-GlcNAc) sugar from 
uridine-5’-diphosphate-N-acetylglucosamine (UDP-GlcNAc) to serine/threonine 
residues, which will further be referred to as “O-GlcNAcylation”. Many nuclear and 
cytoplasmic proteins are O-GlcNAcylated due to different physiological stimuli (Perez-
Cervera et al. 2013).  
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OGT is a member of the GT-B superfamily of glycosyltransferases, and was first 
identified in 1984 by Hart et al. It is the only enzyme in mammals that catalyzes an O-
linked glycosylation using UDP-GlcNAc, the final product of the hexosamine 
biosynthesis pathway (HBP). This nutrient sensing pathway is at the center of sugar, 
amino acid, and fatty acid metabolic pathways as shown in Figure 9. 
 
Figure 9: UDP-GlcNAc is linked to numerous metabolic pathways. Glutamine from 
protein metabolism, glucose from carbohydrate metabolism, acetyl-CoA from lipid 
metabolism, ATP from energy production, and uridine from nucleotide metabolism are 
all necessary compounds for the hexosamine biosynthetic pathway which ultimately 
produces UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is then used by OGT 
to catalyze GlcNAcylation of serine or threonine residues on target proteins. Figure 
modified from (Hanover, Krause, and Love 2012). 
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O-GlcNAcylation is a dynamic process, with proteins being GlcNAcylated 
depending on different cellular stimuli (Walgren et al. 2003). It is also a unique 
modification in that it does not occur on extracellular/lumenal proteins like other protein 
glycosylation modifications, instead, the GlcNAc moiety is found on cytoplasmic and 
nuclear proteins (Kearse and Hart 1991). The OGT gene resides on the X-chromosome 
and is essential for embryonic stem cell viability and mouse ontogeny (O’Donnell et al. 
2004). Loss of OGT in T-lymphocytes leads to apoptosis, while loss of OGT in 
fibroblasts leads to cell growth arrest (O’Donnell et al. 2004). Studying the physiological 
effects of OGT is further complicated by the enormous number of proteins that are O-
GlcNAcylated (Bond and Hanover 2015). For example, endothelial nitric oxide synthase 
(eNOS), the enzyme that synthesizes nitric oxide and helps maintain homeostasis of 
blood vessels is inhibited by O-GlcNAcylation (Nalvarte et al. 2016; Musicki et al. 
2005), and is subsequently linked to diabetes associated erectile dysfunction. 
Calcium/calmodulin-dependent kinase IV (CaMKIV), a kinase that mediates Ca2+ 
induced gene expression and is essential for proper immune response, inflammation 
regulation, and T-cell development, requires O-GlcNAcylation for proper function 
(Racioppi and Means 2008; Dias et al. 2009). O-GlcNAcylation has also been associated 
with Tau protein, which forms pathological aggregates in Alzheimer’s disease. By 
competing with phosphorylation of Tau, a O-GlcNAcylation is suggested to provide a 
protective effect against aggregate formation (Grundke-Iqbal et al. 1986; Liu et al. 2004).   
OGT exists in three isoforms termed mitochondrial OGT (mOGT), 
nucleocytoplasmic OGT (ncOGT), and short OGT (sOGT) (Kornfeld et al. 1964). The 
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ncOGT and sOGT isoforms are both found in the nucleus as well as the cytoplasm, while 
the mOGT isoform is present in the mitochondrial matrix (Lubas et al. 1997). The 
isoforms differ in the lengths of tetratricopeptide repeats (TPRs), with ncOGT having the 
most repeats as well as being the isoform that interacts with TET family proteins 
(Hanover et al. 2003). The O-GlcNAc moiety is removed by O-GlcNAcase (OGA), 
which is the only known enzyme capable of removing this modification (Love, Krause, 
and Hanover 2010). O-GlcNAc moieties are dynamically added and removed by OGT 
and OGA, respectively, and is termed “O-GlcNAc cycling.” The addition of the O-
GlcNAc moiety is thought to serve a similar function to protein phosphorylation in that it 
can either be recognized by other proteins, act as a localization signal, modulate the DNA 
binding activity, or increase the stability of the protein, however, the resulting action is 
not always reciprocal. 
Many of the numerous proteins that OGT modifies are transcription factors and 
epigenetic regulators involved in gene expression (Lewis and Hanover 2014). 
Transcription factors such as pancreatic/duodenal homeobox-1 protein (Pdx-1), Sp1, c-
myc, and nuclear factor kappa B (NF-κB) are just a few of the essential transcription 
factors that are GlcNAcylated with varying downstream effects. Since UDP-GlcNAc, the 
substrate for OGT, is the end product of the hexosamine biosynthesis pathway (HBP), the 
amount of O-GlcNAcylation in a cell is linked to cellular nutrient metabolism and 
provides a direct link between cellular nutrition and gene expression (Kornfeld et al. 
1964; Hanover, Krause, and Love 2012). In addition, OGT has also been proposed to 
GlcNAcylate histones, however this has been controversial and remains to be validated 
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(Chen et al. 2013; Gagnon et al. 2015). O-GlcNAcylation has also been identified on 
RNA polymerase II, directly affecting gene transcription machinery (Comer and Hart 
2001). O-GlcNAcylation of histone modifying proteins is yet another function of OGT. 
Co-activator associated arginine methyltransferase 1 (CARM1) is a histone 
methyltransferase essential for activating gene during mitosis; Sakabe and Hart found 
that when OGT is overexpressed in HeLa cells, CARM1 did not localize to the correct 
position and there was an increase in abnormal chromosomal bridge formation (Sakabe 
and Hart 2010; Comer and Hart 2001). OGT also associates with the H3K4 
methyltransferase MLL5 (mixed lineage leukemia 5), a trithorax family protein that 
regulates cell cycle progression and hematopoiesis (Ding et al. 2015; Chen et al. 2013). 
Ding et al. depleted OGT in HeLA cells and subsequently found drastically decreased 
protein levels of MLL5 with unchanged mRNA expression levels, suggesting O-
GlcNAcylation is involved in protein stability of MLL5. O-GlcNAcylation of host cell 
factor 1 (HCF1) also regulates its stability (Capotosti et al. 2011; Deplus et al. 2013). 
HCF1 is a component of the MLL/SET complex that methylates H3K4 and results in 
transcriptional activation; it is also involved in the regulation of the cell cycle (Julien and 
Herr 2003; Milne et al. 2002).  
TET proteins have also been found to be O-GlcNAcylated, leading to the 
proposition that TET proteins are regulated by this post-translational modification and 
adding another link between nutrition and gene regulation (F.-T. Shi et al. 2013; Vella et 
al. 2013). Using observations that OGT immunoprecipitates with TET1, which is highly 
expressed in embryonic stem (ES) cells, Shi et al. hypothesized that OGT might be post-
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translationally regulating TET1’s enzymatic activity. They first demonstrated that TET1 
could be O-GlcNAcylated, and then used small double stranded interfering RNA 
(siRNA) oligonucleotides to knockdown TET1 and OGT in mouse embryonic stem (ES) 
cells. They observed increased differentiation of cells in either TET1 or OGT knockdown 
cells, thus linking these two proteins to repression of developmentally-associated genes. 
To elucidate how TET1 might be regulated by OGT and O-GlcNAcylation, they used 
mouse ES cells that were depleted of OGT and found that there was a drastic decrease in 
the level of TET1 protein even though mRNA levels of TET1 remained unaffected, 
suggesting that GlcNAcylation is required for TET1 stability. Then, they cultured 293T 
cells that expressed TET1 and varying levels of OGT and found that increasing OGT 
increased TET1 protein levels in a dose-dependent manner, further supporting the notion 
that OGT stabilizes TET1. As O-GlcNAcylation competes with phosphorylation, the 
evidence above, as from many other papers, suggest that this modification acts as an 
additional regulatory mechanism of TET proteins (Bauer et al. 2015). TET2 and TET3 
also demonstrate a link with OGT and have been suggested to promote GlcNAcylation of 
the SET1/COMPASS H3K4 methyltransferase complex (Deplus et al. 2013). With such 
unique and far-reaching effects, OGT in the context of TET proteins and 5hmC leads to 
the possibility of unidentified gene regulation pathways and encourages further 
investigation (Balasubramani and Rao 2013).  
Hypothesis 
The close connection between TET proteins, OGT, and localization to chromatin 
raises another intriguing question: could OGT catalyze glycosylation of DNA? The near 
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1:1 ratio of TET2 and OGT found in CHiP-Seq studies suggests more than a simple 
enzymatic relationship where OGT is recruited to GlcNAcylate TET proteins/histones 
(Vella et al. 2013). Precedents of nucleotide glycosylation have been detected in lower 
organisms; T-even bacteriophages glycosylate their own DNA using T4-β-
glucosyltransferase (T4-βGT) as protection from bacterial endonucleases (Lunt and 
Newton 1965; Josse and Kornberg 1962; Moréra et al. 1999). In flagellates, hydroxylated 
thymine was glucosylated to create β-D-glucopyranosyloxymethyluracil, which is also 
known as base J (Cliffe et al. 2012). OGT and T4-BGT share some similarities and both 
belong to the same family of glycosyltransferases and with the aforementioned data lead 
us to the hypothesis that OGT may glycosylate 5hmC in mammals to play a role in 
regulation of genomic function either as a new epigenetic mark or by influencing 5hmC 
function.  
The existing methods for O-GlcNAc detection are primarily for GlcNAcylated 
proteins. Early methods were complicated by the weak bond between the GlcNAc moiety 
and modified serine/threonine residue, making techniques like standard mass 
spectrometry unfavorable. Newer mass spectrometry methods such as electron-capture 
dissociation (ECD), use lower energy electrons and does not break the weak GlcNAc-
protein bond (Vosseller et al. 2006). To improve detection, enrichment of isolated 
GlcNAcylated proteins is required. The two most common antibodies used are RL2 and 
CTD 110.6 (Comer et al. 2001; Snow, Senior, and Gerace 1987). A more sensitive 
enrichment based strategy utilizes an azido-GlcNAc (GlcNAz) analogue with the azide 
group serving as a chemical handle. The analog is taken up by cells and utilized by the 
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cell’s own machinery. Peracetylated N-azido-acetylglucosamine is easily taken up by 
cells, passes through the HBP to form UDP-GlcNAz, and then utilized by OGT to attach 
GlcNAz moieties to substrates. The azide group can then be chemoselectively ligated to 
biotin, enriched by streptavidin pulldown, and further processed for analysis (Kayser et 
al. 1993; Vocadlo et al. 2003; Laughlin et al. 2008; Nandi et al. 2006). An alternative 
method was developed by Khidekel et al. utilizes a Y289L mutant galactosyltransferase 
(GalT1) mutant and an unnatural UDP-azido-galactose analogue (UDP-GalNAz) with an 
azide chemical handle (Khidekel et al. 2004; Tai et al. 2004). The mutant GalT1 transfers 
the modified galactose onto GlcNAcylated substrates and can be ligated to biotin, 
enriched by streptavidin pulldown, and further processed for analysis (Kim 2011; 
Laughlin and Bertozzi 2007). This chemoenzymatic method is outlined in Figure 10.  
 
Figure 10: Chemoenzymatic labeling using a mutant acetylgalactosamine 
transferase (Gal-T1) enzyme. The mutant Gal-T1 enzyme’s mutation allows it to 
catalyze reactions using an azido-analog of its normal acetylgalactosamine substrate. This 
unique reaction places a “chemical handle” onto substrates that are O-GlcNAcylated and 
the azide group can subsequently be biotinylated. Figure taken from Thermofisher.  
 
In this study, we will build upon the previously mentioned methods of GlcNAc 
detection to identify 5-GlcNAc-hmC. This will require the establishment of a true 
GlcNAcylated DNA strand, which we will synthesize using enzymatic methods. Then, 
we will need a reliable, high-yield enrichment method. Following each major reaction, 
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we will purify the DNA product using solid phase reverse immobilization beads. We 
have elected to use T4-βGT to attach the GlcNAc moiety onto a custom designed DNA 
strand. To detect this GlcNAcylated DNA, we will use a chemoenzymatic method 
involving the attachment of an azido-sugar chemical handle onto 5-GlcNAc-hmC, 
subsequent biotinylation of the azide group, and Streptavidin pulldown. Following 
isolation and purification of the final product, we will use PCR amplification and gel 
electrophoresis to validate synthesis of 5-GlcNAc-hmC. The below flowchart 
summarizes our planned course of action.  
 
Figure 11. Establishing a positive control 5-GlcNAc-hmC strand. Products will be 
purified post-reaction using solid phase reverse immobilization (SPRI). A positive 
control strand will be synthesized enzymatically and detected with a modified 
chemoenzymatic labeling method.  
 
To pave the way for future studies, we will also express and purify full-length 
TET2 and OGT proteins.  
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SPECIFIC AIMS 
 
We hypothesize that OGT may glycosylate 5hmC in mammals to play a role in 
regulation of genomic function either as a new epigenetic mark or by influencing 5hmC 
function. For this study, we plan to establish and optimize a sensitive detection method 
for GlcNAcylated DNA and to prepare full-length TET2 and OGT protein for future 
experiments. Specifically, we will:  
1) Create a 5-GlcNAc-hmC positive control DNA strand using modified methods 
of GlcNAcylated protein detection. 
2) Express and purify full-length TET2 protein from Sf9 cells; and,  
3) Express and purify full-length OGT protein from Sf9 cells.  
We hope this study will pave the way for future experiments to determine 1) if a 
GlcNAcylated cytosine residue is present in mammalian cells; and 2) if OGT is capable 
of GlcNAcylation of DNA.  
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METHODS 
T4-BGT GlcNAcylation of 5hmC DNA 
The EpiMark® 5-hmC and 5-mC Analysis Kit (E3317S) was purchased from 
New England BioLabs and the protocol was modified to establish a 5-GlcNAc-hmC 
DNA positive control. UDP-GlcNAc (U4375) was purchased from Sigma Aldrich. The 
following components were mixed in a 1.5 mL reaction tube: double-stranded 5hmC 
DNA, genomic mouse ESC DNA, 30 units of T4-BGT (10 units/µL), 80 µM of UDP-
GlcNAc, 1X NEBuffer 4 (10X), and nuclease-free H2O to a final volume of 50 µL. The 
reaction mixture was incubated overnight at 37oC.  
Solid Phase Reverse Immobilization 
An SPRI bead buffer composed of 20% polyethylene glycol (PEG) 8000 and 2.5 
M NaCl was prepared and used for all subsequent SPRI reactions. Agencourt AMPure 
XP beads (A63880) were purchased from Beckman Coulter. The ratio of sample to SPRI 
beads was varied depending on the size of the DNA fragment we sought to isolate. The 
first part of this SPRI used a ratio of 1:1.8 of sample to beads + SPRI bead buffer to 
collect the larger sized DNA fragments. First, 30 µL of AMPure XP beads + the 
appropriate amount of SPRI bead buffer was added to the sample, mixed well, and 
incubated at room temperature for 5 minutes. The mixture was then placed on a magnetic 
stand for 10-15 minutes. The supernatant was collected and the remainder was washed 
twice with 80% ethanol. The tube was briefly spun down and placed back on the 
magnetic stand to air dry for 10-20 minutes, until all of the ethanol was evaporated. The 
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DNA was then eluted with 20 µL of H2O and the tube was placed on the magnetic stand 
for ~2 minutes. The elution was collected and transferred to a new tube.  
A simultaneous SPRI with a 1:4:1 ratio of sample to beads + SPRI bead buffer to 
isopropanol was performed on the collected supernatant from above to isolate the smaller 
sized DNA fragments. First, the appropriate amount of AMPure XP beads + SPRI bead 
buffer was added to the supernatant, mixed well, and incubated at room temperature for 5 
minutes. The appropriate amount of isopropanol was added, mixed well, and then placed 
on the magnetic stand for 10-15 minutes. The supernatant was removed and discarded. 
The remainder was washed twice with 80% ethanol, spun down, and placed back on the 
magnetic stand to air dry for 10-20 minutes, until all of the ethanol was evaporated. The 
DNA was then eluted with 20 µL of H2O and the tube was placed on the magnetic stand 
for ~2 minutes. The elution was collected and transferred to a new tube.  
Biotinylation of UDP-GalNAz 
  The following reaction was carried out to biotinylate the azide group on GalNAz. 
A Click-iTTM Protein Analysis Detection Kit with Biotin alkyne (C33372) was purchased 
from ThermoFisher and the protocol was modified as follows. First, stock solutions were 
prepared by adding 60 µL of the alkyne solution (Component A supplied by the kit) to 
the reaction buffer (Component B supplied by the kit). A second stock solution was made 
by adding 500 µL of H2O to Component E supplied by the kit (Reaction Buffer Additive 
2). A vial of Reaction Buffer Additive 1 (Component D supplied by the kit) was prepared 
fresh on the day of use by adding 100 µL H2O. 100 µL of the reaction buffer (Component 
A + Component B) was added to a reaction tube containing the azide-labeled sample. 
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H2O was added to a final volume of 80 µL. The solution was vortexed for 5 seconds. 5 
µL of CuSO4 (Component C) was added and the solution was vortexed for 5 seconds. 5 
µL of Reaction Buffer Additive 1 was added and the solution was vortexed for 5 seconds, 
and then incubated at room temperature for 2-3 minutes. 10 µL of Reaction Buffer 2 was 
added and the solution was vortexed for 5 seconds. The tube was then rotated end-over-
end for 20 minutes. Afterwards, SPRI purification was performed using the same 
protocol from SPRI#2 above.  
Polymerase Chain Reaction Amplification 
 The final product was amplified using polymerase chain reaction with the 
following cycle time: 
1x 95oC 3 minutes 
23x 
95oC 15 seconds 
60oC 30 seconds 
68oC 30 seconds 
1x 68oC 5 minutes 
 
The PCR product was run on a 2% agarose gel and visualized using a ChemiGenius 
Bioimaging System. Taq DNA Polymerase with ThermoPol Buffer (M0267L) was 
purchased from New England BioLabs. 10 mM dNTP mix was purchased from 
Invitrogen.  
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RESULTS 
 
T4 β-Glucosyltransferase Reaction using UDP-GlcNAc  
 We first needed to confirm the attachment of a GlcNAc moiety onto 5-hmC via β-
glucosyltransferase, a viral enzyme that normally utilizes UDP-glucose. To test this, we 
followed the protocol supplied by the New England BioLabs Epimark 5hmC Detection 
kit, but substituted UDP-glucose with UDP-GlcNAc. Following the reaction, the 
glycosylated products would not be subject to digestion by MspI, an enzyme that cleaves 
the internal cytosine of methylated and hydroxymethylated CCGG motifs (C-5mC-G-G 
and C-5hmC-G-G). The 5hmC control DNA and unmodified control DNA were supplied 
by the kit and are identical in sequence except for the modified cytosine at the restriction 
CCGG site (see appendix for sequence). The following table represents the 5 reactions 
that were carried out in Trial #1.  
Table 6. β-glucosyltransferase Reaction Components. Reactions A and B are control 
reactions to verify MspI digestion as well as T4-βGT activity. Reactions C, D, and E 
were intended to demonstrate the effects on T4-βGT using a non-native substrate, UDP-
GlcNAc.    
 
Reaction 
Component 
Reaction A Reaction B Reaction C Reaction D Reaction E 
Nuclease-
free ddH2O 
18.25 µL 19 µL 18.25 µL 17.25 µL 15.25 µL 
5hmC 
Control 
DNA 
2.5 µL 2.5 µL 2.5 µL 2.5 µL 2.5 µL 
NEBuffer 4 2.5 µL 2.5 µL 2.5 µL 2.5 µL 2.5 µL 
UDP-
Glucose  
1 µL 1 µL - - - 
UDP-
GlcNAc 
- - 1 µL 2 µL 4 µL 
T4-βGT 0.75 µL - 0.75 µL 0.75 µL 0.75 µL 
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Following MspI digestion, polymerase chain reaction, and gel separation, the following 
gel demonstrated ineffective MspI digestion.  
 
Figure 12: β-Glucosyltransferase Reaction Verification. Lanes 1, 2, 3, 4, and 5 
correspond with reactions A, B, C, D, and E from the above table. Lane 6 is a no-
template PCR control.  
 
We suspected the concentration of the supplied 5hmC control DNA strand was 
too low, and attempted to remedy this with the addition of carrier DNA. We also wanted 
to test the activity of the supplied MspI enzyme. To do this, we set up the following 
reaction in a PCR tube and incubated for 1 hour at 37oC. Per New England BioLabs 
recommendation, BSA was added to reduce enzyme loss and to stabilize enzymes in 
reaction.  
5 µL of plasmid DNA (536.2 ng/µL) 
2 µL of NEBuffer 4 
2 µL of 10x BSA 
1 µL MspI 
10 µL of H2O 
 
A B C D E 
1 2 3 4 5 6 
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We ran the product on a 1% agarose gel, pictured below, and verified that MspI was 
capable of digesting the plasmid DNA as depicted in the figure below.  
 
Figure 13: MspI digestion verification #1. 1 kb base pair ladder. Lane 1 is the digested 
plasmid DNA and lane 2 is undigested plasmid DNA.  
 
After verifying the supplied MspI was not defective, we sought to remedy the low 
concentration of supplied 5hmC DNA by supplementing the T4-βBGT reaction with 
plasmid DNA as a carrier. The below figure demonstrates that even with carrier DNA, 
MspI did not fully digest the control 5hmC DNA.  
1 2 
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Figure 14: MspI digestion verification Trial #2. 100 bp ladder. Lane 1 is the 
undigested 5hmC sample from Reaction B of β-Glucosyltransferase Reaction 
Verification Trial #1. Lane 2 represents the product of an attempted MspI digestion 2 uL 
of 5hmC control DNA supplemented with 5 µL of plasmid DNA (536.2 ng/µL). Lane 3 
is only the plasmid DNA and Lane 4 is a no-template PCR control. 
 
 In a further attempt to validate MspI digestion, which is critical for determining 
whether the T4-βGT reaction is valid when using the non-native nucleotide sugar, UDP-
GlcNAc, we contacted New England BioLabs with our issue and they kindly sent new 
100 bp DNA control strands (unmodified, 5mC, and 5hmC). The following table details 
the reaction components using the newly supplied DNA.  
1 2 3 4 
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Table 7. MspI Digestion Verification Trial #3 Reaction Components. Reactions A 
through C used the 5hmC control DNA strand while reactions D through F used the 
unmodified control DNA strand. Reactions B and E served as negative controls and did 
not contain the MspI enzyme. Reactions A and C were used to compare the effects of 
carrier DNA when the 5hmC control DNA was used; Reactions D and F compared the 
effects of using carrier DNA when unmodified control DNA was used.  
 
Reaction 
Component 
Reaction A Reaction B Reaction C Reaction D Reaction E Reaction F 
Nuclease-
free ddH2O 
13 µL 13 µL 8 µL 13 µL 13 µL 8 µL 
NEBuffer 4 2 µL 2 µL 2 µL 2 µL 2 µL 2 µL 
BSA 2 µL 2 µL 2 µL 2 µL 2 µL 2 µL 
Unmodified 
Control 
DNA 
- - - 2 µL 2 µL 2 µL 
5hmC 
Control 
DNA 
2 µL 2 µL 2 µL - - - 
Carrier 
Plasmid 
DNA 
- - 5 µL - - 5 µL 
MspI 1 µL - 1 µL 1 µL - 1 µL 
 
 The results of the above reactions are depicted in the below figure.  
 
Figure 15: MspI digestion verification #3. 100 bp ladder. Lane 1 is the undigested 
5hmC sample from Reaction B of β-Glucosyltransferase Reaction Verification Trial #1. 
Lanes 2, 3, 4, 5, 6, and 7 correspond to the products of Reactions A-F from the above 
table. Lane 9 is a no-template control.  
1 2 3 4 5 6 7 8 
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 The results indicate that although the newly supplied control DNA strands were 
subject to moderate MspI digestion, the reaction still did not meet our needs. Due to these 
failed efforts, we decided to design custom unmethylated, methylated, and 
hydroxymethylated DNA strands that we could order in greater amounts (see appendix 
for sequences). Upon receiving the oligos, we used Taq polymerase to anneal and extend 
the ends (Stemmer et al. 1995) and successfully demonstrated MspI cleavage as shown in 
the figure below.  
 
Figure 16: MspI digestion verification with custom methylated DNA strand. The 
ladder is a 100 base pair ladder. The DNA strand is 103 basepairs with a single restriction 
site in the middle. After overnight MspI digestion, a strong signal is shown underneath 
the 100 basepair fragment.   
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 We then moved forward with the T4-βGT glycosylation reaction using UDP-
GlcNAc as shown in the figure below.  
 
Figure 17. T4-βGT GlcNAcylation of 5hmC dsDNA. The first lane is a positive control 
that demonstrates blocked MspI digestion after the addition of UDP-glucose onto 5hmC. 
The second lane used the same reaction conditions, but substituted UDP-glucose with 
UDP-GlcNAc. The third lane shows a negative control where T4-βGT was not added and 
the 5hmC dsDNA was effectively digested by MspI.  
 
Solid Phase Reverse Immobilization  
 An essential piece of our plan is purifying the DNA after each reaction. Solid 
phase reverse immobilization using paramagnetic DNA binding beads relies on a specific 
ratio of beads to sample. A higher ratio of beads to sample results in binding of smaller 
1 2 3 
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DNA fragments and vice versa. To optimize an SPRI purification for a fragment around 
100 bps, we tested three ratios: 1:1, 1:2, and 1:4 of sample to beads. The results are 
shown below.  
 
Figure 18: Solid phase reverse immobilization bead to sample ratio test. 100 base 
pair ladder. The first lane represents a 1:4 dilution of the 5hmC control DNA while the 
fifth lane represents a 1:10 dilution of DNA. Lane 2 is a 1:1 ratio; Lane 3 is a 1:2 ratio; 
Lane 4 is a 1:4 ratio.  
 
TET2 Protein Expression in Sf9 Insect Cells 
 We planned to use TET2 protein for in vitro experiments for this thesis as well as 
for future experiments in the Shi lab and thus wanted to express and purify recombinant 
full-length TET2 wild-type protein. To achieve large scale protein production, we 
decided to use a baculovirus expression vector system. A conjugated TET2-FLAG virus 
was prepared and graciously donated by Dr. Hao Chen, of Dr. Yang Shi’s Lab at Boston 
Children’s Hospital. A Coomassie stain was performed on infected cells to verify 
expression of full-length TET2 and is shown below.  
1 2 3 
1 
4 5 
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Figure 19: Coomassie stain of Infected Sf9 cells. Full-length TET2 protein is indicated 
by a band around the 250 kDa ladder mark.  
 
To determine an appropriate titer for future large-scale protein production, we 
seeded a 6-well plate with Sf9 cells and infected the wells with 0 µL, 10 µL, 40 µL, or 
150 µL of virus. Cells were harvested at 48 hours and 54 hours post-infection and a 
Western blot was performed to confirm TET2 protein expression.  
 45 
 
Figure 20: TET2 Expression in infected Sf9 cells – Western blot. When harvested at 
54 hours post-infection, the expression of TET2 is highest. At 40 µL, a noticeable 
difference is noticed in protein expression as compared to 10 µL. At 150 µL, the protein 
expression is not significantly greater than with 40 µL.   
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DISCUSSION 
To determine whether 5-GlcNAc-hmC exists in mammalian cells, we first wanted 
to establish a positive control using the phage T4-βGT enzyme and a hydroxymethylated 
DNA strand as described by Chen et al. The New England BioLabs Epimark 5hmC and 
5mC detection kit seemed like the perfect starting point because it supplied a fair amount 
of T4-βGT, a 100 bp hydroxymethylated control DNA strand, as well as a restriction 
enzyme verification method. After glycosylation, the product would be verified using 
MspI, an enzyme that digests unmethylated, methylated, and hydroxymethylated CCGG 
sites, but is blocked when the internal cytosine is glycosylated. Our initial experiment 
sought to determine the effects of using UDP-GlcNAc as a substrate for T4-βGT, but the 
negative control (Reaction B – no T4-βGT) was not digested by MspI as expected. See 
Figure 12, lane B.  
Without a method to verify glycosylation, downstream experiments to establish a 
positive control would be futile. Therefore, we tested the digestion capability of the 
supplied MspI enzyme. Fortunately, the enzyme was fully capable of digestion (see 
Figure 13). This lead to the hypothesis that the supplied 5hmC DNA was too diluted to 
maintain its double stranded conformation and thus inhibited MspI digestion. We tried 
adding carrier DNA to bolster the concentration (Figure 14) as well as using a newly 
supplied DNA strand (Figure 15). While the digestion was slightly better than our first 
experiment, it still did not meet our needs. We concluded that the NEB supplied DNA, 
with a concentration of 0.1 ng/µL was simply too diluted.  
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We decided to design our own 5hmC and 5mC DNA strand that we could order in 
greater concentrations. After annealing and an overnight MspI digestion, we were able to 
demonstrate that cleavage of the ~100 bp strand was successful (Figure 16). With this 
solid first step, we could proceed to verify whether BGT could indeed utilize UDP-
GlcNAc as a substrate, which at the time of writing is ongoing.  
 An essential component of our planned detection method involves solid phase 
reverse immobilization (SPRI) purification of DNA. After reactions like T4-βGT 
glycosylation, the DNA product must be rid of nonessential buffer components for the 
subsequent reactions. SPRI uses magnetic beads that bind DNA fragments and can be 
optimized to bind certain sized fragments (DeAngelis, Wang, and Hawkins 1995). Our 
control strands were around 100 bp and thus we tested ratios of 1:1, 1:2, and 1:4 sample 
to beads. Our data indicate that a 1:4 ratio yielded the most DNA (Figure 17).  
 Finally, in preparation for future experiments, we expressed full-length TET2 
protein in Sf9 insect cells. We performed a preliminary verification of protein expression 
and purification of TET2 from the insect cells is ongoing (Figures 19 and 20).  
 The revelation of the active cytosine demethylation pathway via successive 
oxidation of 5mC broadened our understanding of gene expression. In addition, the 
discovery that the oxidized intermediates also played roles in gene expression added 
another level of complexity. This new base could mean a new level of control for gene 
expression. We have yet to answer the question of whether this modification exists in 
physiological conditions. OGT is becoming more and more recognized as an important 
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protein, along with the GlcNAc moiety. It has recently been implicated in regulating 
feeding behavior (Lagerlöf et al. 2016).  
The results from this thesis help set a starting point for ongoing experiments in the 
Shi Lab to determine the existence of 5-GlcNAc-hmC. Future work will involve moving 
forward with the planned chemoenzymatic and metabolic labeling methods of detection.  
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APPENDIX 
EpiMark® 5-hmC and 5-mC Analysis Kit Mark 5hmC Control DNA Sequence 
5’- CAGTGAAGTTGGCAGACTGAGCCAGGTCCCACAGATGCAGTGACCGGAGT 
CATTGCCAAACTCTGCAGGAGAGCAAGGGCTGTCTATAGGTGGCAAGTCA-3’ 
The internal cytosine of the MspI/HpaII site (CCGG) is 5-hydroxymethylated.  
EpiMark® 5-hmC and 5-mC Analysis Kit Mark Forward Primer Sequence 
5’- CA GTG AAG TTG GCA GAC TGA GC – 3’ 
EpiMark® 5-hmC and 5-mC Analysis Kit Mark Reverse Primer Sequence 
5’- CTG ACT TGC CAC CTA TAG ACA GC – 3’ 
Custom 5mC DNA Sequence 
5’ - CAG TGA AGT TGG CAG ACT GAG CCA GGT CCC ACA GAT GCA 
GT(methylC)GAC (methylC)GG A(methylC)G TCA TTG CCA AAC TCT GCA GGA 
GAG CAA GGG CTG TCT ATA GGT GGC AAG TCA – 3’ 
The custom 5mC DNA sequence contains a three methylated cytosines in a concentrated 
region in the middle of the 102 base pair sequence. A single CCGG restriction site is 
located 43 residues from the 5’ end. Digestion of this sequence with MspI results in a 45 
base pair sequence and a 57 base pair sequence.  
Custom 5hmC DNA Sequence 
5’ - CAG TGA AGT TGG CAG ACT GAG CCA GGT CCC ACA GAT GCA GTC 
GAC 5hmCGG ACG TCA TTG CCA AAC TCT GCA GGA GAG CAA GGG CTG 
TCT ATA GGT GGC AAG TCA – 3’ 
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